Risk and prognosis of adult primary immune thrombocytopenia

Expert Review of Hematology

Volumn 5, Issue 2, 2012, Pages 219-228

  Frederiksen, Henrik ^a,b   Christiansen, Christian Fynbo ^a   Norgaard, Mette ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

bleeding risk; comorbidity; epidemiology; incidence; ITP; prognosis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ASEPTIC MENINGITIS; BRAIN HEMORRHAGE; CHILL; COMORBIDITY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FRAGILITY FRACTURE; GASTROINTESTINAL HEMORRHAGE; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; MORBIDITY; MORTALITY; MUCOSAL BLEEDING; OUTCOME ASSESSMENT; PREVALENCE; PRIMARY IMMUNE THROMBOCYTOPENIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOSIS; WEIGHT GAIN; BLEEDING;

HEMORRHAGE; HUMANS; INFECTION; PROGNOSIS; RISK ASSESSMENT; THROMBOCYTOPENIA;

EID: 84864100793     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.7     Document Type: Review

References (63)

1. Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur. J. Haematol. 83(2), 83-89 (2009).
2. Feudjo-Tepie MA, Robinson NJ, Bennett D. Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. J. Thromb. Haemost. 6(4), 711-712 (2008).
3. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 94(3), 909-913 (1999).
4. Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a populationbased study and literature review. Int. J. Hematol. 93(3), 329-335 (2011).
5. Landgren O, Gridley G, Fears TR, Caporaso N. Immune thrombocytopenic purpura does not exhibit a disparity in prevalence between African American and White veterans. Blood 108(3), 1111-1112 (2006).
6. Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br. J. Haematol. 122(6), 966-974 (2003).
7. Schoonen WM, Kucera G, Coalson J et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br. J. Haematol. 145(2), 235-244 (2009).
8. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J. Thromb. Haemost. 4(11), 2377-2383 (2006).
9. Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P, Barbui T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 77(1), 31-33 (1991).
10. Nørgaard M, Jensen AO, Engebjerg MC et al. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish populationbased cohort study. Blood 117(13), 3514-3520 (2011).
11. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97(9), 2549-2554 (2001).
12. Segal JB, Powe NR. Accuracy of identification of patients with immune thrombocytopenic purpura through administrative records: a data validation study. Am. J. Hematol. 75(1), 12-17 (2004).
13. Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am. J. Hematol. 85(3), 174-180 (2010).
14. DiFino SM, Lachant NA, Kirshner JJ, Gottlieb AJ. Adult idiopathic thrombocytopenic purpura. Clinical findings and response to therapy. Am. J. Med. 69(3), 430-442 (1980).
15. Guthrie TH, Jr, Brannan DP, Prisant LM. Idiopathic thrombocytopenic purpura in the older adult patient. Am. J. Med. Sci. 296(1), 17-21 (1988).
16. den Ottolander GJ, Gratama JW, de Koning J, Brand A. Long-term followup study of 168 patients with immune thrombocytopenia. Implications for therapy. Scand. J. Haematol. 32(1), 101-110 (1984).
17. Ben-Yehuda D, Gillis S, Eldor A. Clinical and therapeutic experience in 712 Israeli patients with idiopathic thrombocytopenic purpura. Israeli ITP Study Group. Acta Haematol. 91(1), 1-6 (1994).
18. Nozaki H, Tanaka K, Shimizu M et al. A clinical study of patients with idiopathic thrombocytopenic purpura. Tokai J. Exp. Clin. Med. 14(3), 231-236 (1989).
19. Stefanini M. Idiopathic thrombocytopenic purpura (ITP): an analysis of 1,122 cases. "Allergic" versus "autoimmune" forms. Nouv. Rev. Fr. Hematol. 32(2), 129-135 (1990).
20. Thompson RL, Moore RA, Hess CE, Wheby MS, Leavell BS. Idiopathic thrombocytopenic purpura. Long-term results of treatment and the prognostic significance of response to corticosteroids. Arch. Intern. Med. 130(5), 730-734 (1972).
21. Watson-Williams EJ, Macpherson AI, Davidson S. The treatment of idiopathic thrombocytopenic purpura; a review of ninety-three cases. Lancet 2(7040), 221-226 (1958).
22. Picozzi VJ, Roeske WR, Creger WP. Fate of therapy failures in adult idiopathic thrombocytopenic purpura. Am. J. Med. 69(5), 690-694 (1980).
23. Schiavotto C, Rodeghiero F. Twenty years experience with treatment of idiopathic thrombocytopenic purpura in a single department: results in 490 cases. Haematologica 78(6 Suppl. 2), 22-28 (1993).
24. Provan D, Stasi R, Newland AC et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115(2), 168-186 (2010).
25. Enger C, Bennett D, Forssen U, Fogarty PF, McAfee AT. Comorbidities in patients with persistent or chronic immune thrombocytopenia. Int. J. Hematol. 92(2), 289-295 (2010).
26. Enger C, Bennett D, Dawson KL, Aivado MA, Theodore D, McAfee AT. Hepatobiliary laboratory abnormalities among patients with chronic or persistent immune thrombocytopenia (ITP). Ann. Hepatol. 10(2), 188-195 (2011).
27. Feudjo-Tepie MA, Le RG, Beach KJ, Bennett D, Robinson NJ. Comorbidities of idiopathic thrombocytopenic purpura: a population-based study. Adv. Hematol. 2009, 963506 (2009).
28. Doan CA, Bouroncle BA, Wiseman BK. Idiopathic and secondary thrombocytopenic purpura: clinical study and evaluation of cases over a period of 28 years. Ann. Int. Med. 53(5), 861-876 (1960).
29. Guidry JA, George JN, Vesely SK, Kennison SM, Terrell DR. Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur. J. Haematol. 83(3), 175-182 (2009).
30. Bussel JB, Cheng G, Saleh MN et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med. 357(22), 2237-2247 (2007).
31. Page LK, Psaila B, Provan D et al. The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. Br. J. Haematol. 138(2), 245-248 (2007).
32. Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica 90(6), 829-832 (2005).
33. Michel M, Rauzy OB, Thoraval FR et al. Characteristics Andoutcome of immune thrombocytopenia in elderly: results from a single center case-controlled study. Am. J. Hematol. 86(12), 980-984 (2011).
34. Linares M, Cervero A, Colomina P et al. Chronic idiopathic thrombocytopenic purpura in the elderly. Acta Haematol. 93(2-4), 80-82 (1995).
35. Bizzoni L, Mazzucconi MG, Gentile M et al. Idiopathic thrombocytopenic purpura (ITP) in the elderly: clinical course in 178 patients. Eur. J. Haematol. 76(3), 210-216 (2006).
36. Vianelli N, Valdre L, Fiacchini M et al. Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. Haematologica 86(5), 504-509 (2001).
37. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch. Intern. Med. 160(11), 1630-1638 (2000).
38. Stasi R, Willis F, Shannon MS, Gordon-SmiTheC. Infectious causes of chronic immune thrombocytopenia. Hematol. Oncol. Clin. North Am. 23(6), 1275-1297 (2009).
39. Thomsen RW, Schoonen WM, Farkas DK et al. Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study. Ann. Intern. Med. 151(8), 546-555 (2009).
40. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 104(4), 956-960 (2004).
41. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011. evidence-based practice guideline for immune thrombocytopenia. Blood 117(16), 4190-4207 (2011).
42. Zaja F, Baccarani M, Mazza P et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 115(14), 2755-2762 (2010).
43. Stasi R, Newland AC. ITP: a historical perspective. Br. J. Haematol. 153(4), 437-450 (2011).
44. Naganathan V, Jones G, Nash P, Nicholson G, Eisman J, Sambrook PN. Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch. Intern. Med. 160(19), 2917-2922 (2000).
45. Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann. Rheum. Dis. 70(6), 956-960 (2011).
46. Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR. Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J. Natl Cancer Inst. 96(9), 709-711 (2004).
47. Godeau B, Lesage S, Divine M, Wirquin V, Farcet JP, Bierling P. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 82(5), 1415-1421 (1993).
48. Godeau B, Caulier MT, Decuypere L, Rose C, Schaeffer A, Bierling P. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br. J. Haematol. 107(4), 716-719 (1999).
49. Godeau B, Chevret S, Varet B et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 359(9300), 23-29 (2002).
50. Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 78(6 Suppl. 2), 35-40 (1993).
51. Jensen AO, Nørgaard M, Engebjerg MC et al. Predictors for splenectomy among patients with primary chronic immune thrombocytopenia: a population-based cohort study from Denmark. Ann. Hematol. 90(2), 207-212 (2011).
52. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104(9), 2623-2634 (2004).
53. Yong M, Thomsen RW, Schoonen WM et al. Mortality risk in splenectomised patients: a Danish population-based cohort study. Eur. J. Intern. Med. 21(1), 12-16 (2010).
54. Schwartz PE, Sterioff S, Mucha P, Melton LJ 3rd, Offord KP. Postsplenectomy sepsis and mortality in adults. JAMA 248(18), 2279-2283 (1982).
55. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. J. Infect. 43(3), 182-186 (2001).
56. Arnold DM, Dentali F, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann. Intern. Med. 146(1), 25-33 (2007).
57. Cooper N, Stasi R, Cunningham-Rundles S et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br. J. Haematol. 125(2), 232-239 (2004).
58. Godeau B, Porcher R, Fain O et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter Phase 2 study. Blood 112(4), 999-1004 (2008).
59. Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113(20), 4834-4840 (2009).
60. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am. J. Hematol. 81(1), 19-25 (2006).
61. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 85(2), 351-358 (1995).
62. Quiquandon I, Fenaux P, Caulier MT, Pagniez D, Huart JJ, Bauters F. Reevaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on cases. Br. J. Haematol. 74(2), 223-228 (1990)
63. Kuter DJ, Bussel JB, Lyons RM et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371(9610), 395-403 (2008).